整合素、干预和强化抑制血小板IIb/IIIa受体的整合素治疗试验

Current interventional cardiology reports Pub Date : 1999-12-01

Thel

{"title":"整合素、干预和强化抑制血小板IIb/IIIa受体的整合素治疗试验","authors":"Thel","doi":"","DOIUrl":null,"url":null,"abstract":"Eptifibatide (Integrelin, Corr Therapeutics, South San Francisco, CA) is a cyclic heptapeptide competitive inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that has a short half-life. The results of the initial dose-finding and phase III trials are reviewed and the ongoing Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial are described.","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1999-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Integrilin, Intervention, and the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy Trial.\",\"authors\":\"Thel\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Eptifibatide (Integrelin, Corr Therapeutics, South San Francisco, CA) is a cyclic heptapeptide competitive inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that has a short half-life. The results of the initial dose-finding and phase III trials are reviewed and the ongoing Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial are described.\",\"PeriodicalId\":80270,\"journal\":{\"name\":\"Current interventional cardiology reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current interventional cardiology reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current interventional cardiology reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

eptifitide (integrinin, Corr Therapeutics, South San Francisco, CA)是一种半衰期短的血小板糖蛋白(GP) IIb/IIIa受体的环七肽竞争性抑制剂。本文回顾了初始剂量发现和III期试验的结果，并描述了正在进行的整合素治疗对血小板IIb/IIIa受体的增强抑制(ESPRIT)试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Integrilin, Intervention, and the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy Trial.

Eptifibatide (Integrelin, Corr Therapeutics, South San Francisco, CA) is a cyclic heptapeptide competitive inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that has a short half-life. The results of the initial dose-finding and phase III trials are reviewed and the ongoing Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial are described.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current interventional cardiology reports

自引率

0.00%

发文量

期刊最新文献

Infectious Agents, Antibiotics, and Coronary Artery Disease. Local Drug Delivery During Percutaneous Coronary Intervention. Historical Aspects of Transcatheter Closure of the Patent Ductus Arteriosus. Summary and Comparison of Atrial Septal Defect Closure Devices. Restenosis: Relationship with Thrombosis.